HyperfineHYPR
Recorded

Hyperfine 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration49 minParticipants8

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good afternoon, and welcome to Hyperfine's third quarter 2026 earnings conference call. Currently, all participants are in listen-only mode. Following management's prepared remarks, we will open the call for questions. If you would like to ask a question at that time, please press star then the number one on your telephone keypad to raise your hand and enter the queue. If you would like to withdraw your question at any time, please press star one again. As a reminder, this call is being recorded. I would now like to turn the call over to Webb Campbell from Gilmartin Group for introductory disclosures.

Webb CampbellVP

You may begin. Thank you for joining today's call.

Webb CampbellVP

Earlier today, Hyperfine, Inc. released financial results for the quarter ended September 30, 2026. A copy of the press release is available on the company's website as well as sec.gov. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities law and made pursuant to the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results, or performance are forward-looking statements. All forward-looking statements, including without limitation, those relating to our operating trends and future financial performance, expense management, market opportunity, commercial and international expansion, regulatory approvals, and product development are based upon our current estimates and various assumptions.

Webb CampbellVP

These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the risk factor section of our latest periodic filing with the Securities and Exchange Commission. This conference call contains time-sensitive information and is accurate only as of today's live broadcast. Hyperfine, Inc. disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. With that, I will turn the call over to Maria Sainz, President and Chief Executive Officer.

Maria SainzPresident and CEO

Good afternoon, and thank you for joining us. On the call with me today is the Chief Administrative Officer and Chief Financial Officer, Brett Hale. The financial results in the third quarter were the strongest in Hyperfine's history. We delivered records across the P&L, revenue, gross profit, and gross margin, along with our narrowest operating loss and our lowest quarterly net cash burn. This is not just a great quarter, it marks the beginning of a new trajectory. Revenue was a record $6 million, up 53% sequentially and 73% year-over-year. Gross margin was a record 56.7%. Net cash burn fell 29% sequentially to $5.6 million, and for the first time, quarterly revenue exceeded net cash burn. Brett will walk you through the details.

Maria SainzPresident and CEO

I want to step back and reflect on where we are, who we are, the significant opportunity in front of us to advance brain health and drive meaningful long-term value for our shareholders. Hyperfine is transforming from our origins as a highly innovative niche medical technology company to our present and future as a broad-based medical and wellness platform with a vision to improve brain health globally. Over my more than three decades in health technology, I have witnessed the trends that have shaped this industry over time to improve the delivery of health solutions. I have a strong conviction that the trends that are now shaping the future of health technology represent significant tailwinds for Hyperfine. First, any health tech innovation is now measured on both clinical and economic impact. The correlation between clinical and economic value for our Swoop system is strong.

Maria SainzPresident and CEO

The Swoop system improves care while delivering compelling ROI, reducing cost of care, and improving patient workflow. Second, AI plays an increasingly prominent role in healthcare decisions and delivery. AI robotics is leading the way. AI imaging is fast following. We believe the field needs a diagnostic platform like the Swoop system to realize the potential AI imaging represents in decentralizing and democratizing the field. Without a hardware platform that renders brain imaging scalable and available broadly close to the community, AI imaging will not reach its full potential. Third, healthcare is expanding beyond medical use to wellness and prevention, serving both patients and consumers. An accessible brain imaging platform like the Swoop system enables the use of brain imaging at an accelerated pace in the emerging field of wellness, longevity, and concierge brain health.

Maria SainzPresident and CEO

We are seeing increasing interest in the Swoop system from memory clinics, from wellness, longevity, and concierge practices where accessible brain imaging can support the evaluation and follow-up of individuals over time. We are building a fundamentally strong business with incredible opportunity and potential right in front of us. As we scale and drive revenue growth, margin expansion, and operating leverage, we unlock an increasing number of opportunities for our core technology. We have built a solid proprietary position in miniaturized MRI, with applications inside hospitals and across health systems in ICUs, EDs, and clinics. We have expanded into outpatient care in neurology offices and globally through our distribution partners, and we are now driving an emerging and very large opportunity to also build a brain wellness business. We complement conventional MRI, and we enable the AI ecosystem to drive the scale it needs in AI imaging.

Maria SainzPresident and CEO

This is the new Hyperfine. Turning to the execution that is fueling our success. Our third quarter revenue was driven organically by well-balanced contributions from all three business verticals. The hospital business remains our largest commercial vertical and an important source of validation of our unique technology and its clinical and economic value proposition. Over the past five quarters, the Swoop system has moved beyond use in critical care toward broader routine clinical use across ICUs and emergency departments, with emerging use in hospital-based clinics, postoperative neurosurgical workflows, and mobile deployments. Health systems are where the hospital opportunity gets bigger. Roughly 70% of U.S. hospitals belong to a health system or IDN. In the third quarter, we had several new and follow-on orders and placements from health systems.

Maria SainzPresident and CEO

The process with health systems takes longer because it involves regional, divisional, or national approvals and procurement steps, and the first placement in a new health system is usually the most involved one. After the first placement, follow-on orders build on what is already in place: contracting, approvals, implementation, and clinical champions. We started seeing traction in this segment with the launch of Model 2, and it has now become a meaningful component of our revenue. As we enter the first full annual capital planning cycle since Model 2 launch, we believe health systems represent a growing opportunity. Use of the Swoop system in hospitals continues to increase as adoption spreads from the ICU alone to the ICU, ED, and other sites of care. Each placement drives utilization and generates clinical and economic data. Together, they create clinical and executive champions, and those champions drive follow-on orders across the system.

Maria SainzPresident and CEO

That is the land-and-expand model that we are building in hospitals. In the office, we see continued adoption across a broadening range of settings, from general neurology and memory clinics to the initial concierge practices, as well as the strong use of Swoop system in existing installations. This quarter, the NEURO PMR study was published in the peer-reviewed Journal of Neuroimaging. As a reminder of the results, in a blinded review, portable MRI showed 92% concordance in identifying pathology with conventional MRI, and 98% including clinical history, and patients prefer portable MRI four to one. An important milestone for both our office and hospital businesses in the third quarter was the completion of enrollment in the Contrast PMR study. We remain on track to submit a 510(k) application to the FDA by year-end 2026.

Maria SainzPresident and CEO

Contrast broadens the clinical utility of the Swoop system in hospitals and offices, and in outpatient settings, contrast brain MRI is reimbursed under a dedicated CPT code 70553. Published clinical evidence, strong patient preference, and a path to contrast imaging with established reimbursement are building the case for brain MRI in the neurology office. Beyond our U.S. hospital and office opportunities, we have also built a solid international foundation. We launched Model 2 in Europe and the U.K. mid-year following CE and UKCA marking, and we have sold Model 2 into four international markets, with very positive feedback from initial users. In October, our latest Optive AI software also received CE and UKCA marking, bringing its noise correction and workflow improvements to customers in Europe and the U.K. We also recently signed an exclusive distribution agreement for Kuwait and UAE, extending our reach into the Middle East markets.

Maria SainzPresident and CEO

Our distributor model allows us to expand globally without a proportionate increase in operating expense. In summary, beyond the strong headline numbers, the Hyperfine team delivered in every part of our business in the third quarter. We launched the latest Optive AI software, published NEURO PMR, completed Contrast PMR enrollment, launched Model 2 in international markets, and expanded our distribution into the Middle East. With that, I will turn the call over to Brett to review our financial performance and guidance.

Brett HaleChief Administrative Officer and CFO

Thank you, Maria. The third quarter delivered strong performance from revenue to cash burn reduction. I will walk through the third quarter results and how they support our full-year guidance and the long-term trajectory of the business. These results demonstrate the operating leverage in our business model. Revenue increased 53% sequentially, while operating expenses increased less than 2%. Compared with the second quarter, record revenue and record gross margin generated $1.4 million of additional gross profit against just $0.2 million of additional operating expense. That translated into a narrower operating loss alongside a 29% reduction in net cash burn. Turning to the details. Revenue for the third quarter of 2026 was a record $6.0 million compared to $3.4 million in the third quarter of 2025, representing an increase of $2.5 million or 73% year-over-year and an increase of 53% from the second quarter of 2026.

Brett HaleChief Administrative Officer and CFO

In the third quarter, we sold 14 units compared to eight units in the prior year period, an increase of 75%. Third quarter growth reflected contributions from all three commercial verticals: U.S. hospital, U.S. office, and international. As Marie described, commercial momentum included new and follow-on health system orders, expansion across hospital sites of care, adoption in neurology offices and initial concierge practices, and the international rollout of Model 2. This growth was organic and broad-based with no one-time items. Revenue growth reflected higher unit sales and a record average selling price. Service revenue also increased 31% year-over-year, reflecting continued expansion of our installed base. Gross profit for the third quarter of 2026 was a record $3.4 million compared to $1.8 million in the third quarter of 2025, an increase of $1.5 million or 83%.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day